Literature DB >> 29450988

Salso-bromo-iodine thermal water: a nonpharmacological alternative treatment for postnasal drip-related cough in children with upper respiratory tract infections.

I La Mantia1, G Ciprandi2, A Varricchio2, F Cupido2, C Andaloro3.   

Abstract

Postnasal drip (PND)-related cough is a very common symptom in patients with upper respiratory tract infections (URTIs). At present, there is not a standard treatment for postnasal drip and postnasal drip-related cough. The aim of this pilot study was to evaluate the efficacy of a specific salso-bromo-iodine thermal water containing hyaluronic acid and grapefruit seed extract (SBI-H-GSE) comparing it with a normal saline solution in children with URTIs who refer PND-related symptoms. The study was randomized, single-blind, and controlled. Study group (75 children) was treated with SBI-H-GSE and control group (65 children) was treated with a normal saline solution; both compounds were administered by nasal nebulization with Rinowash nasal douche twice/day for 10 days a month for 3 consecutive months. Parent Cough-Specific Quality of Life questionnaire (PC-QOL) average score, the prevalence of symptoms and signs related to post-nasal drip, nasal mucociliary transport time (NMTT), duration and number of URTI episodes, antibiotic usage and days of absence from school were evaluated at baseline and after treatment. SBI-H-GSE therapy shows better and statistically significant trend after treatment when compared to control group for PC-QOL average score (p=0.011), NMTT (p=0.047), symptoms and signs related to post-nasal drip (all p<0.005, except for the cobblestone appearance of the mucosa), duration (in days) with URTI symptoms (p=0.023) and a usage of antibiotic therapy (p=0.011). The current randomized-controlled pilot study demonstrated that SBI-H-GSE solution was effective in the treatment of children with URTIs who refer PND-related symptoms.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29450988

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  6 in total

1.  Broncalt®, class II medical device, in patients with chronic upper airways disease: a survey in clinical practice.

Authors:  Gian Franco Cupido; Matteo Gelardi; Ignazio La Mantia; Salvo Emanuele Aragona; Claudio Vicini; Giorgio Ciprandi; Italian Study Group On Inflammatory Otorhinolaryngological Disorders
Journal:  Acta Biomed       Date:  2019-07-10

2.  Broncalt®, class II medical device, in patients with acute upper airways disease: a survey in clinical practice.

Authors:  Gian Franco Cupido; Matteo Gelardi; Ignazio La Mantia; Salvo Emanuele Aragona; Claudio Vicini; Giorgio Ciprandi; Italian Study Group On Inflammatory Otorhinolaryngological Disorders
Journal:  Acta Biomed       Date:  2019-07-10

3.  VAS for assessing the perception of antihistamines use in allergic rhinitis.

Authors:  Giorgio Ciprandi; Ignazio La Mantia
Journal:  Acta Biomed       Date:  2019-07-03

4.  Broncalt®, class II medical device, in patients with chronic relapsed upper airways disease: a survey in clinical practice.

Authors:  Gian Franco Cupido; Matteo Gelardi; Ignazio La Mantia; Salvo Emanuele Aragona; Claudio Vicini; Giorgio Ciprandi; Italian Study Group On Inflammatory Otorhinolaryngological Disorders
Journal:  Acta Biomed       Date:  2019-07-10

5.  Oral health in children with sleep-disordered breathing: a cross-sectional study.

Authors:  Calogero Grillo; Ignazio La Mantia; Graziano Zappala; Salvatore Cocuzza; Giorgio Ciprandi; Claudio Andaloro
Journal:  Acta Biomed       Date:  2019-07-10

6.  Inflammation, infection, and allergy of upper airways: new insights from national and real-world studies.

Authors:  Attilio Varricchio; Ignazio La Mantia; Francesco Paolo Brunese; Giorgio Ciprandi
Journal:  Ital J Pediatr       Date:  2020-02-10       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.